TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27798345

Group type: EXPERIMENTAL
Intervention: Biofortified orange maize (OM) - 2 meals/d, 6 d/wk for 6 mo
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Biofortified orange maize (OM)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: White maize (WM) - 2 meals/d, 6 d/wk for 6 mo
Number of subjects: 1024
Study: 25543421

Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and auricular acupressure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride capsules (20 mg, once a day)
Number of subjects: 60
Study: 24045520

Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT) plus latanoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Timolol plus latanoprost (fixed combination therapy)
Number of subjects: 30
Study: 20604697

Group type: EXPERIMENTAL
Intervention: Promoting CARE suicide prevention program
Number of subjects: 593
Study: 18156457

Group type: EXPERIMENTAL
Intervention: Heparin-reduced group (50% reduced standard doses of nonfractionated heparin)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (full dose of heparin)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Heparin-reduced group
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study: 16177595

Group type: EXPERIMENTAL
Intervention: Submaximal steady-state exercise (cycle ergometry at 40% of peak oxygen capacity) for 25 minutes
Number of subjects: 65

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CFS patients (without comorbid FM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CFS + FM patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CFS patients (pre- and postexercise)
Number of subjects: 65
Study: 12860546

Group type: EXPERIMENTAL
Intervention: Patellar tendon graft reconstruction
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft reconstruction
Number of subjects: 65

Group type: COMPARATOR
Intervention: Both grafts
Number of subjects: 65
Study: 11036880

Group type: EXPERIMENTAL
Intervention: 100 microgram 1-thyroxine daily (Thyroxine group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No therapy (Control group)
Number of subjects: 60
Study: 8899359

Group type: EXPERIMENTAL
Intervention: Individualized behavioral feeding intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study: 1794835

Group type: EXPERIMENTAL
Intervention: 40 mg afloqualone
Number of subjects: 12

Group type: COMPARATOR
Intervention: 15 mg diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5 g/kg ethanol
Number of subjects: 12
Study: 6305185

Group type: EXPERIMENTAL
Intervention: Diet 1 (low-fiber diet with spinach every other day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet 2 (fiber in fruits and vegetables including spinach every other day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diet 3 (same as Diet 2 but with cauliflower instead of spinach)
Number of subjects: 12
Study: 30586008

Group type: EXPERIMENTAL
Intervention: Vitamin E (VitE)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 30285459

Group type: EXPERIMENTAL
Intervention: Semitendinosus tendon graft with intact tibial insertion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with free semitendinosus tendons
Number of subjects: 64
Study: 26749289

Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Lantus insulin glargine (IGlar)
Number of subjects: 751
Study: 25027157

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture penetrating the skin
Number of subjects: 400

Group type: COMPARATOR
Intervention: Skin-touch placebo
Number of subjects: 400

Group type: COMPARATOR
Intervention: No-touch placebo needles
Number of subjects: 400

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 400
Study: 23114140

Group type: EXPERIMENTAL
Intervention: hiDLI plus IL‐2
Number of subjects: 49

Group type: COMPARATOR
Intervention: mix‐HSCT only
Number of subjects: 49
Study: 19344229

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (COL) 3.75 grams/day
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (COL)
Number of subjects: 1018
Study: 17570999

Group type: EXPERIMENTAL
Intervention: Combination of frequency doubling technology (FDT) perimetry and short-wavelength perimetry (SWAP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Short-wavelength perimetry (SWAP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Frequency doubling technology (FDT) perimetry
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Combination of FDT and SWAP
Number of subjects: 109
Study: 14980754

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Standardized acupuncture
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control acupuncture (invasive sham)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All groups (individualized, standardized, control)
Number of subjects: 192
Study: 12167181

Group type: EXPERIMENTAL
Intervention: 1.5 g daily MgSO(4) infusion applied the day before surgery, just after operation, and 4 days following surgery
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no magnesium treatment)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 1.5 g daily MgSO(4) infusion
Number of subjects: 148
Study: 9649905

Group type: EXPERIMENTAL
Intervention: High-frequency QRS components during balloon inflation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard 12-lead ECG ST-segment deviations
Number of subjects: 19
Study: 8583478

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2655682

Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CBZ-CR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional carbamazepine (CBZ-C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both formulations (CBZ-C and CBZ-CR)
Number of subjects: 8
Study: 792985

Group type: EXPERIMENTAL
Intervention: 13‐Nle‐M (0.4 mug/kg‐h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 6
Study: 30782893

Group type: EXPERIMENTAL
Intervention: HORYZONS plus treatment as usual (TAU)
Number of subjects: 170

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: HORYZONS plus TAU
Number of subjects: 170
Study: 28418763

Group type: COMPARATOR
Intervention: Combined‐modality treatment in HD7 (N = 627; median follow‐up, 120 months)
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved‐field (IF)‐RT in HD10 (N = 1,190; median follow‐up, 98 months)
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Involved‐field RT in HD8 (N = 1,064; median follow‐up, 153 months)
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at baseline in HD11 (N = 1,395; median follow‐up, 106 months)
Number of subjects: 4276

Group type: EXPERIMENTAL
Intervention: ABVD-treated patients receiving 20 Gy instead of 30 Gy IF‐RT in HD11
Number of subjects: 4276
Study: 25219291

Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 190306

Group type: COMPARATOR
Intervention: Current reference treatments
Number of subjects: 190306
Study: 23992914

Group type: EXPERIMENTAL
Intervention: Screening instrument before and at the end of radiation treatment
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control group (no screening instrument)
Number of subjects: 568
Study: 21306277

Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 158

Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 158
Study: 19758710

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopic powered adenoidectomy (TEPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Curettage adenoidectomy (CA)
Number of subjects: 40
Study: 17305759

Group type: EXPERIMENTAL
Intervention: True eradication therapy
Number of subjects: 184
Study: 15242467

Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg/d)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study: 11302355

Group type: EXPERIMENTAL
Intervention: Sensory focusing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Music distraction
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 9018647

Group type: EXPERIMENTAL
Intervention: Methotrexate (single agent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methotrexate + Misoprostol (control)
Number of subjects: 40
Study: 7876405

Group type: EXPERIMENTAL
Intervention: 80 mg orlistat three times a day at mid-meal (group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg orlistat at mid-meal and 0.5, 1, and 2 hr after mid-meal (group B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo at mid-meal and 0.5, 1, and 2 hr after mid-meal (group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo at mid-meal (group B)
Number of subjects: 16
Study: 3422693

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1-g single dose)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2-g each)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ceftizoxime and Cefoxitin
Number of subjects: 99
Study: 31676260

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks (∼15 min HIIT + 30 min sport activities, 3 times/week)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 38
Study: 30734406

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT-BN)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT-A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both FBT-BN and CBT-A
Number of subjects: 110
Study: 27443596

Group type: EXPERIMENTAL
Intervention: 1-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Number of subjects: 600

Group type: COMPARATOR
Intervention: 6-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Number of subjects: 600
Study: 25458830

Group type: EXPERIMENTAL
Intervention: Calorie-sufficient, carbohydrate-free diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard diet (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 7
Study: 23326612

Group type: EXPERIMENTAL
Intervention: Mass antibiotic distribution (specifics not provided)
Number of subjects: 48
Study: 21911317

Group type: EXPERIMENTAL
Intervention: Flecainide (3 mg/kg of weight, n=40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Amiodarone (30 mg/kg weight, n=40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Propafenone (8.5 mg/kg of weight, n=40)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (n=40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 160
Study: 18243375

Group type: EXPERIMENTAL
Intervention: Health-education intervention
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 827
Study: 16813627

Group type: EXPERIMENTAL
Intervention: Early ambulation (EA) - first walk postoperative day 1 or 2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed ambulation (DA) - first walk postoperative day 3 or 4
Number of subjects: 60
Study: 15727424

Group type: EXPERIMENTAL
Intervention: Chloroquine (150 mg daily starting 1 day after surgery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (standard treatment without chloroquine)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 18
Study: 11086771

Group type: EXPERIMENTAL
Intervention: 5 days of ampicillin/sulbactam (Group 1)
Number of subjects: 317

Group type: COMPARATOR
Intervention: 24 hours of ampicillin/sulbactam followed by 4 days of placebo (Group 2)
Number of subjects: 317
Study: 8817406

Group type: COMPARATOR
Intervention: Salt-restriction placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Salt-restriction cilazapril (2.5 mg daily)
Number of subjects: 39
Study: 1579872

Group type: EXPERIMENTAL
Intervention: Intradiscal chymopapain
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intradiscal normal saline
Number of subjects: 60
Study: 3907278

Group type: EXPERIMENTAL
Intervention: Perphenazine decanoate (PD) 100 mg intramuscularly every two weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perphenazine enanthate (PE) 100 mg intramuscularly every two weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perphenazine enanthate (PE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Perphenazine decanoate (PD)
Number of subjects: 50
Study: 31440874

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Contact intervention
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 164
Study: 29720733

Group type: EXPERIMENTAL
Intervention: Dasatinib added to intensive induction and consolidation chemotherapy and administered as a single agent for 1-year maintenance.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Dasatinib treatment
Number of subjects: 89
Study: 27936206

Group type: EXPERIMENTAL
Intervention: Exercise group (N = 59)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (N = 21)
Number of subjects: 80
Study: 24762958

Group type: EXPERIMENTAL
Intervention: Molecularly targeted therapy based on tumour molecular profiling
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 100
Study: 23165659

Group type: EXPERIMENTAL
Intervention: Sildenafil plus testosterone (10-g transdermal gel for 14 weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sildenafil plus placebo
Number of subjects: 140
Study: 20517210

Group type: EXPERIMENTAL
Intervention: Cortexin (10 mg/d intramuscular for 10 days) along with standard therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no cortexin)
Number of subjects: 30
Study: 17562666

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 160
Study: 15847730

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 459
Study: 11807700

Group type: EXPERIMENTAL
Intervention: Home sampling kit mailed directly to home address (n=4500)
Number of subjects: 30439

Group type: EXPERIMENTAL
Intervention: Reply card mailed to home address with option to order home sampling kit (n=4500)
Number of subjects: 30439

Group type: COMPARATOR
Intervention: Usual care (n=21,439)
Number of subjects: 30439
Study: 10360853

Group type: EXPERIMENTAL
Intervention: Propofol 20 mg (P-20)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Propofol 40 mg (P-40)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (intralipid)
Number of subjects: 69
Study: 8530603

Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2200257

Group type: EXPERIMENTAL
Intervention: Metoprolol OROS (14/190 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study: 6271426

Group type: EXPERIMENTAL
Intervention: Propranolol-prepared patients
Number of subjects: 20
Study: 28237177

Group type: EXPERIMENTAL
Intervention: EFJ group
Number of subjects: 322

Group type: COMPARATOR
Intervention: non-EFJ group
Number of subjects: 322
Study: 29457191

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 46
Study: 27212228

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IIV3
Number of subjects: 100
Study: 24366930

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (alloSCT)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Conventional postremission therapy
Number of subjects: 370
Study: 22389708

Group type: EXPERIMENTAL
Intervention: Standard polyethylene glycol‐based bowel cleansing preparation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Un‐prepped flexible sigmoidoscopy
Number of subjects: 12

Group type: COMPARATOR
Intervention: 24‐hour clear liquid diet followed by un‐prepped flexible sigmoidoscopy
Number of subjects: 12
Study: 19755327

Group type: EXPERIMENTAL
Intervention: GuardWire distal protection
Number of subjects: 501
Study: 17974864

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg/day
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg/day
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 15734296

Group type: EXPERIMENTAL
Intervention: Standard oral treatment (200 ml water + 100 mg danazol capsule + 3 x 500 mg paracetamol tablets + 2 x 500 mg sulfasalazine tablets)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard + lipid-rich meal treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard + 800 ml water treatment
Number of subjects: 8
Study: 11788220

Group type: EXPERIMENTAL
Intervention: 10 mg of phosphorothioate-modified 15-mer antisense ODN
Number of subjects: 85

Group type: COMPARATOR
Intervention: Saline vehicle (control)
Number of subjects: 85
Study: 10528036

Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b plus prednisolone (200 microg of interferon gamma‐1b given three times per week subcutaneously and 7.5 mg of prednisolone daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prednisolone alone (7.5 mg daily, which could be increased to 25 to 50 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b plus prednisolone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 18
Study: 7730453

Group type: EXPERIMENTAL
Intervention: Structured intervention using selected items of the Brazelton Neonatal Behavioral Assessment Scale
Number of subjects: 60

Group type: COMPARATOR
Intervention: Talk with a pediatrician about general problems of infant health care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Structured intervention
Number of subjects: 60
Study: 2373132

Group type: EXPERIMENTAL
Intervention: d-sotalol (0.25, 0.50, 1, 2 mg.kg‐1 i.v. and 100 mg oral dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: dl-sotalol (1 mg.kg‐1 i.v.)
Number of subjects: 6
Study: 38627

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31571560

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 28
Study: 31127932

Group type: EXPERIMENTAL
Intervention: UBE2L3 expression in CeD patients on GFD
Number of subjects: 0

Group type: COMPARATOR
Intervention: UBE2L3 expression
Number of subjects: 0
Study: 28672317

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 721

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 721
Study: 25812529

Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB) alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 101

Group type: COMPARATOR
Intervention: IGB followed by HA at IGB removal (6 months)
Number of subjects: 101

Group type: COMPARATOR
Intervention: HA and IGB at 6 months
Number of subjects: 101
Study: 23688842

Group type: EXPERIMENTAL
Intervention: PES users
Number of subjects: 0

Group type: COMPARATOR
Intervention: PES non‐users
Number of subjects: 0
Study: 21135663

Group type: EXPERIMENTAL
Intervention: Nonpharmaceutical interventions (NPIs)
Number of subjects: 10
Study: 20032954

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (800 mg/day, serum lithium concentration 0.8-1.2 mmol/L)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Valproate sodium (20 mg/kg/day, serum valproate concentration between 70 and 125 µg/ml)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lithium carbonate (800 mg/day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Valproate sodium (20 mg/kg/day)
Number of subjects: 125
Study: 16377775

Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii LA1 (2 x 10(9) cfu) for six months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii LA1
Number of subjects: 98
Study: 11214780

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.5 mg four times daily for 9 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.5 mg four times daily for 9 days) + Warfarin (25 mg single dose on the fourth treatment day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Warfarin (25 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levosimendan alone for 3 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levosimendan + Warfarin
Number of subjects: 10
Study: 8894790

Group type: EXPERIMENTAL
Intervention: MgO 3 times a day at a daily dose of 1.0 g (600 mg/day of magnesium)
Number of subjects: 15
Study: 2071263

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) nasal spray
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12